Invivyd, Inc. (IVVD) stock
IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3048% below fair value
$0.47−0.04 (-8.21%)
Close on Nov 18, 2026Market cap $138.68MP/E –Yield –
Invivyd operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Invivyd's operating income for the twelve months ending Jun 30, 2026 was -$112.53M. For fiscal 2025 it was -$55.56M. The highest annual figure on record is -$55.56M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$55.56M | – |
| FY2024 | Dec 31, 2024 | -$176.88M | – |
| FY2023 | Dec 31, 2023 | -$212.76M | – |
| FY2022 | Dec 31, 2022 | -$248.03M | – |
| FY2021 | Dec 31, 2021 | -$226.91M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$45.82M | – |
| Q1 FY2026 | Mar 31, 2026 | -$43.14M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.06M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.92M | – |
| Q4 FY2024 | Dec 31, 2024 | -$19.23M | – |
| Q3 FY2024 | Sep 30, 2024 | -$62.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$49.25M | – |
| Q1 FY2024 | Mar 31, 2024 | -$46.09M | – |
| Q4 FY2023 | Dec 31, 2023 | -$76.75M | – |
| Q3 FY2023 | Sep 30, 2023 | -$43.06M | – |
| Q2 FY2023 | Jun 30, 2023 | -$53.88M | – |
| Q1 FY2023 | Mar 31, 2023 | -$39.07M | – |
| Q4 FY2022 | Dec 31, 2022 | -$48.21M | – |
| Q3 FY2022 | Sep 30, 2022 | -$47.33M | – |
| Q2 FY2022 | Jun 30, 2022 | -$51.75M | – |
| Q1 FY2022 | Mar 31, 2022 | -$100.74M | – |
| Q4 FY2021 | Dec 31, 2021 | -$83.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$60.42M | – |
| Q2 FY2021 | Jun 30, 2021 | -$44.69M | – |
| Q1 FY2021 | Mar 31, 2021 | -$38.71M | – |
| Q3 FY2020 | Sep 30, 2020 | -$48.01M | – |
See a number that looks wrong?